Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis

Jiing-Chyuan Luo, Hsin-Bang Leu, Kuang-Wei Huang, Chin-Chou Huang, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee and Shou-Dong Lee
CMAJ December 13, 2011 183 (18) E1345-E1351; DOI: https://doi.org/10.1503/cmaj.110299
Jiing-Chyuan Luo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jcluo@vghtpe.gov.tw
Hsin-Bang Leu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuang-Wei Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-Chou Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Chih Hou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han-Chieh Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fa-Yauh Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shou-Dong Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Few large population-based studies have compared the incidence of bleeding of gastroduodenal ulcers between patients with and without end-stage renal disease. We investigated the association between ulcer bleeding and end-stage renal disease in patients receiving hemodialysis, and we sought to identify risk factors for ulcer bleeding.

Methods: We performed a nationwide seven-year population study using data from the National Health Insurance Research Database in Taiwan. We identified 36 474 patients with end-stage renal disease who were receiving hemodialysis, 6320 patients with chronic kidney disease and 36 034 controls matched for age, sex and medication use. We performed log-rank testing to analyze differences in survival time without ulcer bleeding among the three groups. We performed Cox proportional hazard regressions to evaluate the risk factors for ulcer bleeding among the three groups and to identify risk factors in patients receiving hemodialysis.

Results: Patients receiving hemodialysis and those with chronic kidney disease had a significantly higher incidence of ulcer bleeding than controls had (p < 0.001). Hemodialysis (hazard ratio [HR] 5.24, 95% confidence interval [CI] 4.67–5.86) and chronic kidney disease (HR 1.95, 95% CI 1.62–2.35) were independently associated with an increased risk of ulcer bleeding. Diabetes mellitus, coronary artery disease, cirrhosis and use of nonsteroidal anti-inflammatory drugs were risk factors for ulcer bleeding in patients with end-stage renal disease who were receiving hemodialysis

Interpretation: Patients with end-stage renal disease who are receiving hemodialysis had a high risk of ulcer bleeding. Diabetes mellitus, coronary artery disease, cirrhosis and the use of nonsteroidal anti-inflammatory drugs were important risk factors for ulcer bleeding in these patients.

Taiwan has the highest incidence and prevalence of end-stage renal disease in the world.1 The approximately 40 000 patients with end-stage renal disease consume 7% (about NT$26 billion) of Taiwan’s health insurance budget for dialysis treatment, especially because 90% of these patients receive hemodialysis rather than peritoneal dialysis.2 In Western and Asian countries, previous studies have suggested that the prevalence of peptic ulcer disease among patients with end-stage renal disease is not higher than in the general population;3–5 however, recent reports show a higher prevalence among patients receiving long-term hemodialysis6,7 and a higher rate of bleeding after the development of ulcers in these patients.8

The pathogenesis and risk factors for ulcers or ulcer bleeding in patients with end-stage renal disease are unclear.9–11 We performed a nationwide population-based cohort study to investigate the association between hemodialysis and bleeding of gastroduodeanl ulcers and to identify the risk factors for ulcer bleeding in patients with end-stage renal disease.

Methods

Data sources

National Health Insurance is a mandatory health insurance program in Taiwan that provides comprehensive coverage for medical care. Up to 96% of the population was enrolled by 2002.12 Claims data are collected in the National Health Insurance Research Database at the National Health Research Institutes. For research purposes, the institute released to the public a cohort dataset for one million randomly selected individuals and a dataset for 46 576 patients with some catastrophic illnesses (e.g., end-stage renal disease, cancer) who were alive in 2000. The institute collected all records for these individuals from 1995 to 2006. There were no statistically significant differences in age, sex and health care costs between the one million randomly sampled individuals and those enrolled in our study. Comprehensive health care data include the enrolment files, claims data, catastrophic illness files and a registry for drug prescriptions.

Each patient’s original identification number was encrypted for privacy in the cohort dataset. The encryption procedure was consistent between datasets so that all claims belonging to each patient could be linked. Because the dataset consisted of de-identified secondary data released to the public for research purposes, this study was exempt from full review by the institutional review board.

Study groups

Our study included almost all patients in Taiwan receiving long-term hemodialysis, as well as age- and sex-matched controls. We did not include patients who had started hemodialysis in the three months before enrolment and those with acute renal failure because of a high rate of ulcer bleeding in patients with critical medical conditions and acute renal failure.15,16

In Taiwan, patients with end-stage renal disease who are in need of long-term (more than three months) renal replacement therapy can apply for a catastrophic illness registration card from the National Health Research Institutes. We identified 36 474 patients with end-stage renal disease who had received a diagnosis of chronic renal failure (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 585) and who had received hemodialysis for more than three months from Jan. 1, 2000 through 2006. We excluded patients receiving peritoneal dialysis and those who had received a kidney transplant before or after enrolment. Figure 1 shows the flow of patients during the course of this study.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Flow of patients with end-stage renal disease undergoing hemodialysis during the seven-year study period. In total, 26 145 patients were alive at the end of follow-up in 2007. *All patients who were excluded from follow-up had died during the study period (28.3% of patients undergoing hemodialysis).

We included controls without kidney disease (absence of ICD-9-CM codes: 580.x–588.x, 250.4x, 274.1x, 283.11, 403.x1, 404.x2, 404.x3, 440.1, 442.1, 447.3, 572.4, 642.1x and 646.2x) from the database in a 1:1 ratio. We matched the controls with patients receiving hemodialysis in terms of age, sex and use of some ulcerogenic medications (nonsteroidal anti-inflammatory drugs [NSAIDs], acetylsalicylic acid [ASA], steroids, ticlopidine and warfarin) and year of enrolment. Medications were identified and classified by use of the National Drug Classification System and the Anatomic Therapeutic Chemical Code, which is an internationally accepted classification system of drugs coordinated by the World Health Organization Collaborating Centre for Drug Statistics Methodology.13

We included a comparison group of 6320 patients with chronic kidney disease (ICD-9-CM codes 582.0, 582.4, 582.8x, 586, 250.4x, 274.1, 403.x1, 404.x2, 404.x3, corresponding to stage 4 and 5 chronic kidney disease) who were identified from the same cohort from the National Health Research Institutes.

We also investigated the covariables age, sex, pre-existing hypertension (ICD-9-CM 401.0–405.99), diabetes mellitus (ICD-9-CM 250.0–250.93), congestive heart failure (ICD-9-CM 428–428.9), coronary artery disease (ICD-9-CM 410–414.9) and cirrhosis of the liver (ICD-9-CM 571.2, 571.5 and 571.6).

Outcomes

The main outcome was the occurrence of ulcer bleeding as the main diagnosis during hospital stay. Bleeding was confirmed by endoscopic examination. The data were obtained from administrative claims (ICD-9-CM 531.0, 531.00, 531.01, 531.2x, 531.4x, 531.6x, 532.0, 532.00, 532.01, 532.2x, 532.4x, 532.6x, 533.0, 533.00, 533.01, 533.2x, 533.4x, 533.6x, 534.0, 534.00, 534.01, 534.2x, 534.4x and 534.6x). We also investigated bleeding-free survival time.

Statistical analysis

All data were expressed as frequency (percentage) or mean and standard deviation. We compared parametric continuous data between groups using the Student t test, and we compared categorical data using the χ2 test and Yates correction or the Fisher exact test. We performed survival analysis using the Kaplan–Meier method, with significance based on the log-rank test. We calculated survival time as being the time from the date of enrolment in the cohort to the date of admission to hospital because of ulcer bleeding. We performed multiple regression analysis using Cox proportional hazard regression analysis. We defined statistical significance as a two-sided p value of less than 0.05.

Results

The demographic data are shown in Table 1. Except for clopidogrel, concurrent use of ulcerogenic medications such as NSAIDs, ASA, steroids, ticlopidine and warfarin was comparable between the hemodialysis group and the control group (p > 0.05). However, comorbidities, including coronary artery disease, hypertension, diabetes, heart failure and cirrhosis were not equivalent between the groups (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1:

Demographic data for patients undergoing hemodialysis, patients with chronic kidney disease and controls from 2001 to 2006

During the seven-year study period, 3004 (3.8%) of the 78 828 people included in this study experienced bleeding of gastroduodenal ulcers. Of these, 2361 were receiving hemodialysis (6.5% of patients with end-stage renal disease), 163 had chronic kidney disease (2.6% of patients with chronic kidney disease) and 480 were controls (1.3% of the controls) (Table 1). The log-rank test and Kaplan–Meier survival analysis showed that there was a significantly higher incidence of ulcer bleeding among patients receiving hemodialysis than among those with chronic kidney disease or among the controls (p < 0.001). The rate of bleeding was significantly higher in the group with chronic kidney disease than in the control group (p < 0.001) (Figure 2).

Figure 2:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2:

Kaplan–Meier estimates of survival time free of peptic ulcer bleeding in patients undergoing hemodialysis, those with chronic kidney disease and controls. *Log rank p < 0.001.

After adjustment for age, sex, hypertension, diabetes, coronary artery disease, heart failure, cirrhosis and the use of NSAIDs, ASA, steroids, clopidogrel, ticlopidine and warfarin, the hazard ratio (HR) for ulcer bleeding was 5.24 times higher (95% confidence interval [CI] 4.67–5.86) in the hemodialysis group and 1.95 times higher (95% CI 1.62–2.35) in the chronic kidney disease group than in the control group (Table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2:

Independent predictors of ulcer bleeding identified by Cox regression analysis

The results of the multivariable analysis are shown in Figure 3. In each stratum, we compared the HRs between patients receiving hemodialysis and controls. Those receiving hemodialysis had a significantly higher risk of ulcer bleeding regardless of age, sex, hypertension, diabetes, coronary artery disease, congestive heart failure, cirrhosis and use of ASA or NSAIDs.

Figure 3:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3:

Adjusted hazard ratios (HRs) for ulcer bleeding in patients receiving hemodialysis. In each stratum, the HRs were compared between patients undergoing hemodialysis and controls. *Each factor was adjusted for all other factors. CI = confidence interval, NSAID = nonsteroidal anti-inflammatory drug.

Cox multivariable regression analysis showed that diabetes, coronary artery disease, cirrhosis and NSAIDs use, but not age, hypertension, heart failure and use of ASA, were risk factors for ulcer bleeding in patients with end-stage renal disease receiving hemodialysis (Table 3).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3:

Risk factors for ulcer bleeding in patients with end-stage renal disease undergoing hemodialysis

Interpretation

We performed a nationwide population-based longitudinal seven-year cohort study. We found that patients undergoing hemodialysis and those with chronic kidney disease had a high risk of ulcer bleeding. Diabetes, coronary artery disease, cirrhosis and use of NSAIDs are important risk factors for ulcer bleeding in patients with end-stage renal disease undergoing hemodialysis.

In a cross-sectional study at a single medical center, Sugimoto and colleagues found that patients undergoing dialysis had higher rates of gastroduodenal ulcers than healthy people with normal renal function (17.8% v. 7.4%).6 In a longitudinal retrospective study, Chen and colleagues found that 18.5% of patients undergoing dialysis (hemodialysis and peritoneal) experienced a symptomatic peptic ulcer during a three-year follow-up period.14 However, they did not include a control group for comparison. We focused on patients undergoing hemodialysis rather than peritoneal dialysis, and we found that patients undergoing hemodialysis had a fivefold higher risk of ulcer bleeding after adjustment for possible confounding variables.

The risk factors and pathogenesis of ulcers and ulcer bleeding in patients with chronic kidney disease and end-stage renal disease include platelet dysfunction, platelet–vessel wall interaction and abnormalities in blood coagulation.11,17 Our results suggest that chronic kidney disease is also an independent risk factor for ulcer bleeding. However, patients undergoing hemodialysis had a higher risk of ulcer bleeding than patients with chronic kidney disease. A possible explanation for this finding is the increased risk of bleeding after the use of anti-coagulants (e.g., heparin) during hemodialysis in patients with existing ulcers or erosions. It is also possible that these patients had impaired healing of ulcers because of intermittent hemodynamic instability in the gastrointestinal tract during hemodialysis.

We found that diabetes, coronary artery disease, cirrhosis and use of NSAIDs were risk factors for ulcer bleeding in patients undergoing hemodialysis. In the general population, a history of ulcer or ulcer bleeding, use of NSAIDs and ASA, and Helicobacter pylori infection are important risk factors for ulcer bleeding.18,19 In a study involving 30 648 patients with end-stage renal disease undergoing hemodialysis, Wasse and colleagues reported that cardiovascular disease, smoking and an inability to walk independently were risk factors for bleeding in the upper gastrointestinal tract.11 Chen and colleagues found that diabetes, congestive heart failure, low albumin levels and receiving peritoneal dialysis were risk factors for peptic ulcers in patients receiving dialysis.14 The dataset used in our study did not include data for smoking and ambulatory status. It also did not include patients undergoing peritoneal dialysis.

The finding that the use of NSAIDs but not ASA is a risk factor is consistent with the findings of Ethier and colleagues, who reported that ASA was not associated with gastrointestinal bleeding in hemodialysis patients,20 and of Jankovic and colleagues, who found that NSAIDs increased the risk of gastrointestinal bleeding in this group.21 Taken together, these results suggest that hemodialysis patients who use NSAIDs and have diabetes, cardiovascular disease or cirrhosis have a higher risk of ulcer bleeding than patients without these factors. In such patients, the use of gastroprotective agents, such as proton-pump inhibitors, should be considered to protect the gastroduodenal mucosa.

Limitations

The findings of this study need to be interpreted in the context of certain limitations. First, the observations were retrospective and based on patients admitted to hospital because of peptic ulcer bleeding. Certain selection biases may exist, and caution must be used when extrapolating the results.

Second, we were unable to assess H. pylori infection, an important risk factor for ulcers and ulcer bleeding,18,22 because the dataset used did not include this information. Nonetheless, previous studies have shown that the prevalence of H. pylori infection in patients with uremia is not higher than in the general population6,23 and that H. pylori infection is not a risk factor for ulcer or recurrent ulcer in uremic patients.14,24

Third, although smoking and alcohol consumption are risk factors for peptic ulcers, information about these factors was not available in the National Health Insurance dataset.

Lastly, we did not evaluate protective factors for peptic ulcer disease, such as the use of gastroprotective agents (proton-pump inhibitors, misoprostol and histamine-2 receptor antagonists). In Taiwan’s National Health Insurance program, the use of proton-pump inhibitors or histamine-2 receptor antagonists is limited to patients with endoscopic reflux esophagitis or peptic ulcer disease.17 Gastroprotective agents are not covered by National Health Insurance for prophylaxis against ulcers or ulcer bleeding, and prescriptions for such prophylactics are not found in the National Health Insurance Research Database.

Conclusion

We found that patients with end-stage renal disease undergoing hemodialysis had a high risk of ulcer bleeding. Diabetes, coronary artery disease, cirrhosis and the use of NSAIDs were important risk factors for ulcer bleeding in this population.

Acknowledgements

The authors thank Miss Pui-Ching Lee (Department of Medicine, Taipei Veterans General Hospital) for statistical consultation.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • Contributors: Jiing-Chyuan Luo conceived the study. He, along with Hsin-Bang Leu and Kuang-Wei Huang, designed the study, performed the analysis and interpretation of data, and drafted and revised the manuscript. Chin-Chou Huang, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee and Shou-Dong Lee contributed to the analysis and interpretation of the data and revising the manuscript. All authors approved the final version of the manuscript submitted for publication.

  • Funding: This work was supported by grants from the Taipei Veteran General Hospital (grant nos. V98C1-051, V99C1-15 and V100C-026).

References

  1. ↵
    US Renal Data System USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 2007.
  2. ↵
    Department of Health. National health insurance annual statistical report. Taiwan: Department of Health; 2004.
  3. ↵
    1. Margolis DM,
    2. Saylor JL,
    3. Geisse G,
    4. et al
    . Upper gastro-intestinal disease in chronic renal failure. Arch Intern Med 1978;138:1214–7.
    OpenUrlCrossRefPubMed
    1. Musola R,
    2. Franzin G,
    3. Mora R,
    4. et al
    . Prevalence of gastro-duodenal lesions in uremic patients undergoing dialysis and after renal transplantation. Gastrointest Endosc 1984;30:343–6.
    OpenUrlPubMed
  4. ↵
    1. Kang JY,
    2. Wu AY,
    3. Sutherland IH,
    4. et al
    . Prevalence of peptic ulcer in patients undergoing maintenance hemodialysis. Dig Dis Sci 1988;33:774–8.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Sugimoto M,
    2. Sakai K,
    3. Kita M,
    4. et al
    . Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int 2009;75:96–103.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Khedmat H,
    2. Ahmadzad-Asl M,
    3. Amini M,
    4. et al
    . Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc 2007;39:1003–7.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cheung J,
    2. Yu A,
    3. LaBossiere J,
    4. et al
    . Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc 2010;71:44–9.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Holden RM,
    2. Harman GJ,
    3. Wang M,
    4. et al
    . Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:105–10.
    OpenUrlAbstract/FREE Full Text
    1. Jankovic SM,
    2. Aleksic J,
    3. Rakovic S,
    4. et al
    . Non-steroidal anti-inflammatory drugs and risk of gastro-intestinal bleeding among patients on hemodialysis. J Nephrol 2009;22:502–7.
    OpenUrlPubMed
  9. ↵
    1. Wasse H,
    2. Gillen DL,
    3. Ball AM,
    4. et al
    . Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003;64:1455–61.
    OpenUrlCrossRefPubMed
  10. ↵
    Bureau of National Health Insurance. 2001 National Health Insurance annual statistical report. Taipei (Taiwan): The Bureau; 2002.
  11. ↵
    World Health Organizing Collaborating Center for Drug Statistics Methodology. ATC index with DDDs 2003. Oslo (Norway): The Center; 2003.
  12. ↵
    1. Chen YT,
    2. Yang WC,
    3. Lin CC,
    4. et al
    . Comparison of peptic ulcer disease risk between peritoneal and hemodialysis patients. Am J Nephrol 2010;32:212–8.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Fiaccadori E,
    2. Maggiore U,
    3. Clima B,
    4. et al
    . Incidence, risk factors, and prognosis of gastro-intestinal hemorrhage complicating acute renal failure. Kidney Int 2001;59:1510–9.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Klebl FH,
    2. Scholmerich J
    . Therapy insight: prophylaxis of stress-induced gastro-intestinal bleeding in critically ill patients. Nat Clin Pract Gastroenterol Hepatol 2007;4:562–70.
    OpenUrlPubMed
  15. ↵
    1. Wu CY,
    2. Wu CH,
    3. Wu MS,
    4. et al
    . A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009;7:427–31.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Huang JQ,
    2. Sridhar S,
    3. Hunt RH
    . Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002;359:14–22.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hsiang KW,
    2. Chen TS,
    3. Lin HY,
    4. et al
    . Incidence and possible risk factors for clinical upper GI events in patients administrating selective cyclooxygenase-2 inhibitors: a prospective, observational, cohort study in Taiwan. Clin Ther 2010;32:1294–303.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Ethier J,
    2. Bragg-Gresham JL,
    3. Piera L,
    4. et al
    . Aspirin prescription and outcomes in hemodialysis patients: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2007;50: 602–11.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Jankovic SM,
    2. Aleksic J,
    3. Rakovic S,
    4. et al
    . Non-steroidal anti-inflammatory drugs and risk of gastro-intestinal bleeding among patients on hemodialysis. J Nephrol 2009;22:502–7.
    OpenUrlPubMed
  20. ↵
    1. Luo JC
    . Gastroprotective strategy in aspirin users. J Chin Med Assoc 2009;72:343–5.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Shousha S,
    2. Arnaout AH,
    3. Abbas SH,
    4. et al
    . Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol 1990; 43:397–9.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Kang JY,
    2. Ho KY,
    3. Yeoh KG,
    4. et al
    . Peptic ulcer and gastritis in uremia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol 1999;14:771–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (18)
CMAJ
Vol. 183, Issue 18
13 Dec 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis
Jiing-Chyuan Luo, Hsin-Bang Leu, Kuang-Wei Huang, Chin-Chou Huang, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Shou-Dong Lee
CMAJ Dec 2011, 183 (18) E1345-E1351; DOI: 10.1503/cmaj.110299

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis
Jiing-Chyuan Luo, Hsin-Bang Leu, Kuang-Wei Huang, Chin-Chou Huang, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Shou-Dong Lee
CMAJ Dec 2011, 183 (18) E1345-E1351; DOI: 10.1503/cmaj.110299
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study
  • The Risk of Major Hemorrhage with CKD
  • Long-Term Risk of Upper Gastrointestinal Hemorrhage after Advanced AKI
  • Upper Gastrointestinal Bleeding in Patients with CKD
  • A Comorbidity Index for Mortality Prediction in Chinese Patients with ESRD Receiving Hemodialysis
  • Google Scholar

More in this TOC Section

  • Bodychecking experience and rates of injury among ice hockey players aged 15–17 years
  • COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
  • Suicidality among sexual minority and transgender adolescents: a nationally representative population-based study of youth in Canada
Show more Research

Similar Articles

Collections

  • Topics
    • Nephrology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire